Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023
84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphoma Durable complete response was measured-68% at 1 month, 61% at 3 months, and 60% at 6 months respectively. DAEJEON, South Korea, June 19, 2023 /PRNewswire/ — Curocell Inc, … Read more